Page 5 - டீபீ கூட்டணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டீபீ கூட்டணி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டீபீ கூட்டணி Today - Breaking & Trending Today

New drug cocktail offers hope to patients with highly drug-resistant tuberculosis

New drug cocktail offers hope to patients with highly drug-resistant tuberculosis
A new three-drug, all-oral, six-month treatment is providing hope to patients in Tajikistan with highly drug-resistant forms of tuberculosis, which until now had limited treatment options and poor prognosis.
Tajikistan is the first country in Central Asia and second in the world after Ukraine to provide access to the novel BPaL regimen to patients suffering from the extensively drug-resistant (XDR-TB) form of tuberculosis under operational research conditions from December 2020. The regimen consists of three drugs bedaquiline, pretomanid and linezolid.
XDR-TB is caused by bacteria resistant to some of the most effective anti-TB drugs and these strains develop from mismanaged treatment of patients with multidrug-resistant TB (MDR-TB). ....

Republic Of , South Africa , South Korea , Khai Lin , Khai Lin Huang , Veriko Mirtskhulava , Scidev Netthat , Sandeep Juneja , Emily Henderson , Tb Alliance , National Tuberculosis Programme , Tb Partnership Global Drug Facility , Un Sustainable Development Goals , World Health Organization , Tuberculosis Foundation , Central Asia , New England Journal , Global Drug Facility , Burnet Institutein Melbourne , குடியரசு ஆஃப் , தெற்கு கொரியா , கை லின் , கை லின் ஹுவாங் , சந்தீப் ஜுனேஜா , எமிலி ஹென்டர்சன் , டீபீ கூட்டணி ,

ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets

ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced a strategic collaboration agreement with TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs.
ZebiAIs platform utilizes vast datasets of high-quality protein-small molecule interaction data and proprietary machine learning (ML) algorithms, applied in partnership with Google Accelerated Science, to discover novel compounds from commercial and virtual libraries. Through the collaboration, TB Alliance will provide funding for ZebiAI to develop small molecule probes against key tuberculosi ....

United States , South Korea , United Kingdom , Thomas Lynch , Ed Koval , Nader Fotouhi , Rick Wagner , Republic Of Koreas Ministry Foreign Affairs , National Institute Of Allergy , Netherlands Ministry Of Foreign Affairs , Melinda Gates Foundation , Global Health Innovative Technology Fund , Cystic Fibrosis Foundation , Zebiai Inc , Indonesia Health Fund , United States Agency For International Development , Tb Alliance , Global Disease Eradication Fund Korea , Germanys Federal Ministry Of Education , Australias Department Of Foreign Affairs , Zebiais Chemome Initiative , Development Office United Kingdom , Korea International Cooperation Agency , United Kingdom Department For International Development , Research Council United Kingdom , Google Accelerated Science ,

New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010

(2)
Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development
NEW YORK, Jan. 28, 2021 /PRNewswire/ The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for accelerating biomedical innovation. However, the effectiveness of public-private partnerships in fighting global health threats had emerged long before this pandemic hit. Over the last decade, such alliances have produced a wide assortment of life-saving technologies targeting diseases that afflict billions in low-income countries, according to a new report from a group of 12 product development partnerships (PDPs) that assesses their impact and future potential. ....

Kostenloser Wertpapierhandel , Willo Brock , Journal Of Health Economics , Study Of Drug Development , Human Development Resource Centre , International Vector Control Consortium , Gracec Product Development Partnerships Pdps , Tufts Center , Medicines Development For Global Health , Tuberculosis Vaccine Initiative , Vaccine Initiative , Tb Alliance , European Vaccine Institute , International Partnership For Microbicides , International Vaccine Institute , Foundation For Innovative New Diagnostics , Senior Vice President , External Affairs , Malaria Venture , Neglected Diseases , International Partnership , Global Health , Innovative New Diagnostics , Drug Development , Pandemic Response Boxes , Diagnostics Pillar ,

People with highly drug-resistant TB to get new three-drug regimen

Treatment of drug-resistant TB in South Africa has been transformed over the past decade.
Most people with the illness no longer have to have daily injections, and treatment is often completed in nine months, compared with 18 to 24 months in the past.
Perhaps most important is that fewer people are dying of drug-resistant TB, and there is less hearing loss, a common side effect of the injections used in the past.
Key to this transformation in our public sector has been the roll-out of the antibiotics, bedaquiline and linezolid.
These two drugs, plus another two, in some cases even four or five, make up drug-resistant TB treatment today. ....

South Africa , Groote Schuur , Western Cape , Eastern Cape , University Of Cape Town , Keertan Dheda , Nelisiwe Ngcobo , Lindsay Mckenna , Francesca Conradie , Us Agency For International Development Usaid , Treatment Action Group , Drug Administration , Wits Health Consortium , World Health Organisation , Tb Alliance , Sa Health Products Regulatory Authority , Wits University , International Development , Products Regulatory Authority , Getting Gauteng , Action Group , Groote Schuur Hospital , Cape Town , மேற்கு கேப் , கிழக்கு கேப் , பல்கலைக்கழகம் ஆஃப் கேப் நகரம் ,

Hundreds in SA with highly drug-resistant TB to get new...

Treatment of drug-resistant forms of tuberculosis (DR-TB) in South Africa has been transformed over the last decade. Most people with DR-TB no longer have to take daily injections and treatment is often completed in nine months, compared to 18-24 months in the past. Maybe most importantly, fewer people are dying of DR-TB and fewer people are suffering hearing loss, a common side effect of injections used in the past.
Key to this transformation in our public sector has been the rollout of the antibiotics bedaquiline and linezolid. These two drugs plus another two, or in some cases even another four or five, make up DR-TB treatment in South Africa today. Broadly speaking, the more resistant someone’s TB has become, the more complicated the treatment combination and the longer the treatment lasts. But that may be about to change with a new three-drug regimen taken for just six months. ....

South Africa , United States , Groote Schuur , Western Cape , Eastern Cape , University Of Cape Town , Keertan Dheda , Nelisiwe Ngcobo , Lindsay Mckenna , Francesca Conradie , Drug Administration , Wits Health Consortium , United States Agency For International Development , Division Of Pulmonology At Groote Schuur Hospital , World Health Organisation , Tb Alliance , Department Of Health , African Health Products Regulatory Authority Sahpra , Us Basedngotreatment Action Group , United States Agency , International Development , United States Food , Action Group , Groote Schuur Hospital , Cape Town , ஒன்றுபட்டது மாநிலங்களில் ,